Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues

被引:114
作者
Miki, Y
Suzuki, T
Tazawa, C
Blumberg, B
Sasano, H
机构
[1] Tohoku Univ, Grad Sch Med, Dept Pathol, Aoba Ku, Sendai, Miyagi 9808575, Japan
[2] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA
关键词
steroid and xenobiotic receptor; CYP3A4; MDR1;
D O I
10.1016/j.mce.2004.12.005
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The steroid and xenobiotic receptor (SXR) has been demonstrated to play an important role in the regulation of the cytochrome P450 3A4 gene (CYP3A4) and multidrug resistance gene 1 (MDR1) by both endogenous and xenobiotic substrates. SXR and its rodent ortholog PXR exhibit marked differences in their ability to be activated by xenobiotic inducers. This suggests that results obtained by rodent models may not always accurately predict responses to the same compounds in humans. SXR expression was demonstrated in the human liver and intestine, but its systemic distribution remains unknown. Therefore in this study, we first characterized the expression of SXR and its target genes CYP3A4, and MDR1 in human adult and fetal tissues using quantitative RT-PCR, immunoblotting, and combined laser capture microscopy and RT-PCR analysis. SXR mRNA and protein are expressed in adult and fetal liver, lung, kidney, and intestine. There is a close association between the expression of SXR and its target genes in all of the tissues examined. The amounts of SXR mRNA in the liver and intestine reached maximal levels in young adults (15-38 years old) and then subsequently decreased to less than half of the maximal levels with aging. These findings demonstrated age-related differences in the body's capacity to metabolize steroids and xenobiotic compounds and suggest an important role for SXR and its target genes, CYP3A4 and MDR1 in this process. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:75 / 85
页数:11
相关论文
共 40 条
[1]   Expression and localization of CYP3A4 and CYP3A5 in human lung [J].
Anttila, S ;
Hukkanen, J ;
Hakkola, J ;
Stjernvall, T ;
Beaune, P ;
Edwards, RJ ;
Boobis, AR ;
Pelkonen, O ;
Raunio, H .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) :242-249
[2]  
Babyatsky M.W., 1999, TXB GASTROENTEROLOGY, P547
[3]   METABOLIC CLEARANCE RATE, BLOOD PRODUCTION, INTERCONVERSION AND TRANSPLACENTAL PASSAGE OF CORTISOL AND CORTISONE IN PREGNANCY NEAR TERM [J].
BEITINS, IZ ;
BAYARD, F ;
ANCES, IG ;
KOWARSKI, A ;
MIGEON, CJ .
PEDIATRIC RESEARCH, 1973, 7 (05) :509-519
[4]   Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction [J].
Bertilsson, G ;
Heidrich, J ;
Svensson, K ;
Åsman, M ;
Jendeberg, L ;
Sydow-Bäckman, M ;
Ohlsson, R ;
Postlind, H ;
Blomquist, P ;
Berkenstam, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) :12208-12213
[5]   SXR, a novel steroid and xenobiotic-sensing nuclear receptor [J].
Blumberg, B ;
Sabbagh, W ;
Juguilon, H ;
Bolado, J ;
van Meter, CM ;
Ono, ES ;
Evans, RM .
GENES & DEVELOPMENT, 1998, 12 (20) :3195-3205
[6]   BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites [J].
Blumberg, B ;
Kang, HJ ;
Bolado, J ;
Chen, HW ;
Craig, AG ;
Moreno, TA ;
Umesono, K ;
Perlmann, T ;
De Robertis, EM ;
Evans, RM .
GENES & DEVELOPMENT, 1998, 12 (09) :1269-1277
[7]   EXPRESSION OF THE MULTIDRUG RESISTANCE GENE-PRODUCT (P-GLYCOPROTEIN) IN HUMAN NORMAL AND TUMOR-TISSUES [J].
CORDONCARDO, C ;
OBRIEN, JP ;
BOCCIA, J ;
CASALS, D ;
BERTINO, JR ;
MELAMED, MR .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1990, 38 (09) :1277-1287
[8]   Cytochrome P450 3A - Ontogeny and drug disposition [J].
de Wildt, SN ;
Kearns, GL ;
Leeder, JS ;
van den Anker, JN .
CLINICAL PHARMACOKINETICS, 1999, 37 (06) :485-505
[9]   cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome p450 [J].
Domanski, TL ;
Finta, C ;
Halpert, JR ;
Zaphiropoulos, PG .
MOLECULAR PHARMACOLOGY, 2001, 59 (02) :386-392
[10]  
Dotzlaw H, 1999, CLIN CANCER RES, V5, P2103